The evolution of iPSC-based cell therapy across autologous and allogeneic pathways
- 1Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Biology, University of California, Los Angeles, CA 90095, USA
- 2School of Basic Medical Sciences, MOE Engineering Research Center of Regenerative Medicine, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center and the MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100191, China
- 3Changping Laboratory, Beijing 102206, China
Abstract
Induced pluripotent stem cell (iPSC)-based treatments have revolutionized regenerative medicine, yielding patient-specific renewable cells without raising ethical concerns related to the use of embryonic stem cells. In two decades, iPSC therapies have advanced from basic research to clinical trials and official approvals. Early research focused on autologous transplantation, exemplified by the 2014 retinal pigment epithelium (RPE) graft. Yet, personalized production obstacles prompted allogeneic schemes relying on HLA cell banks and immunomodified donor cells. Meanwhile, innovations such as chemical reprogramming have revitalized autologous strategies. Today, autologous and allogeneic iPSC therapies complement each other for distinct clinical demands. This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies.
Related
- Cell death pathways and targeting therapeutics in cancer therapy
- Exosome engineering and molecular tools for targeted therapy of brain-infecting pathogens: delivery systems, signaling pathways, and therapeutic applications
- Diversity and evolution of chromatin regulatory states across eukaryotes
- Transcriptional signatures associated with environmental and developmental variation in tobacco aroma-related pathways across cultivars and regions
- Conformational Barrier-Driven Flux Redistribution across Competing Catalytic Pathways Unifies Diverse Enzyme Kinetic Regimes
BibTeX
@article{wang2026evolution,
title = {{The evolution of iPSC-based cell therapy across autologous and allogeneic pathways}},
author = {Anmin Wang and Yunpei Zhang and Hongkui Deng and Mingxia Gu},
journal = {Cell Reports Medicine},
year = {2026},
month = aug,
doi = {10.1016/j.xcrm.2026.102992},
url = {https://doi.org/10.1016/j.xcrm.2026.102992},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The evolution of iPSC-based cell therapy across autologous and allogeneic pathways
AU - Anmin Wang
AU - Yunpei Zhang
AU - Hongkui Deng
AU - Mingxia Gu
PY - 2026
DA - 2026/08/18
JO - Cell Reports Medicine
DO - 10.1016/j.xcrm.2026.102992
UR - https://doi.org/10.1016/j.xcrm.2026.102992
AB - Induced pluripotent stem cell (iPSC)-based treatments have revolutionized regenerative medicine, yielding patient-specific renewable cells without raising ethical concerns related to the use of embryonic stem cells. In two decades, iPSC therapies have advanced from basic research to clinical trials and official approvals. Early research focused on autologous transplantation, exemplified by the 2014 retinal pigment epithelium (RPE) graft. Yet, personalized production obstacles prompted allogeneic schemes relying on HLA cell banks and immunomodified donor cells. Meanwhile, innovations such as chemical reprogramming have revitalized autologous strategies. Today, autologous and allogeneic iPSC therapies complement each other for distinct clinical demands. This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies.
SN - 2666-3791
ER -